California Pharmacist Summer 2025 JB 08052025 2 - Flipbook - Page 23
peer-to-peer
Duration of Edoxaban in Cancer-Associated
Deep Vein Thrombosis: Critical Appraisal of the
ONCO-DVT Trial
Takachika Takimoto, Kyonosuke Miyata, and Aya F. Ozaki
Takachika Takimoto, is a 昀椀fth-year MD candidate, School of Medicine, Fukushima Medical University, Fukushima,
Japan; Kyonosuke Miyata, is a fourth-year undergraduate student, Faculty of Medical Sciences, University of Fukui,
Fukui, Japan; Aya F. Ozaki, BSPharm, PharmD, is Assistant Professor of Clinical Pharmacy, School of Pharmacy and
Pharmaceutical Sciences, University of California, Irvine. All the authors declare no con昀氀icts of interest.
Con昀氀icts of interest: The authors report no con昀氀icts of interest relevant to the content of this article.
Correspondence: Aya F. Ozaki, afozaki@uci.edu
About the Editor: Evidence-Based Practice submissions are coordinated by Associate Editor Cynthia Jackevicius,
BScPhm, PharmD, MSc, BCPS, BCCP, FCSHP, FAHA, FCCP, FCCS, FACC, Professor, Western University of Health
Sciences, Pomona, CA. She reports no con昀氀icts of interest.
Original Article: Yamashita Y, et al. Edoxaban for 12 months versus 3 months in patients with cancer with isolated
distal deep vein thrombosis (ONCO DVT Study): an open-label, multicenter, randomized clinical trial. Circulation.
2023;148:1665-1676. DOI: 10.1161/CIRCULATIONAHA.123.066360
Patient Population: Adult patients with active cancer newly diagnosed with isolated distal deep vein thrombosis
(DVT) were included. Patients on anticoagulation, with pulmonary embolism, or with a life expectancy or prognosis
≤3 months were excluded.
Intervention: Edoxaban 60 mg once daily (30 mg once daily for patients with a creatinine clearance of 30 to 50 mL/
min, a body weight of ≤60 kg, or concomitant use of P-glycoprotein inhibitors) for 12 months (n = 296).
Comparison: Edoxaban 60 mg once daily (30 mg once daily for patients with a creatinine clearance of 30 to 50 mL/
min, a body weight of ≤60 kg, or concomitant use of P-glycoprotein inhibitors) for 3 months (n = 305).
Outcome: The primary endpoint was a composite of symptomatic recurrent venous thromboembolism (VTE) or
VTE-related death at 12 months. The major secondary endpoint was major bleeding at 12 months.
California Pharmacist | vol. 72, no. 2
21
